Company Information

  

Address: 15 CROSBY DRIVE  
City: BEDFORD 
State: MA 
Zip Code: 01730 
Telephone: 781-895-3235 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of the eye using our proprietary, bioresorbable hydrogel platform technology. We use this technology to tailor duration and amount of delivery of a range of therapeutic agents of varying duration in our product candidates. We incorporate FDA approved therapeutic agents, including small molecules and proteins, into our hydrogel technology with the goal of providing extended delivery of drug to the eye. We believe that our extended delivery technology allows us to treat conditions and diseases of both the front and the back of the eye and can be administered through a range of different modalities including intracanalicular inserts, intracameral implants and intravitreal implants.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-2.02NAN/E
12/2017-2.20NAN/E
09/2017-2.27NAN/E
06/2017-2.12NAN/E
03/2017-1.94NAN/E
12/2016-1.80NAN/E
09/2016-1.72NAN/E
06/2016-1.80NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.24Total Liab/Total Assets0.53
Net Inc/Total Assets-1.14Total Liab/Inv Cap0.80
Net Inc/Inv Cap-1.74Total Liab/Comm Equity0.11
Pretax Inc/Net Sales-32.96Interest Coverage Ratio-32.50
Net Inc/Net Sales-32.96Curr Debt/Equity0.21
Cash Flow/Net Sales-26.25LTD/Equity0.48
SG&A/NetSales16.91Total Debt/Equity0.69
Asset Utilization   Liquidity  
Net Receivables Turnover8.08Quick Ratio3.22
Inventory Turnover3.89Current Ratio3.23
Inventory Day Sales0.01Net Rec/Curr Assets0.01
Net Sales/Work Cap0.06Inv/Curr Assets0.00
Net Sales/PP&E0.18  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 0.34 0.49 0.52 0.44
Cost of Goods Sold 0.08 0.11 0.13 0.10
Selling & Admin Exps 5.49 5.18 7.47 10.56
Operating Income -13.46 -12.72 -15.20 -18.34
Interest Exp 0.49 0.49 0.49 0.47
Pretax Income -13.77 -13.10 -15.57 -18.69
Other Income 0.18 0.10 0.12 0.11
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -13.77 -13.10 -15.57 -18.69

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 62.91 41.54 51.17 66.05
Receivables - Total 0.17 0.23 0.28 0.21
Inventories - Total 0.14 0.12 0.13 0.09
Total Current Assets 64.48 43.34 52.45 68.33
Net Property, Plant & Equipment 10.60 10.48 10.22 9.62
Total Assets 76.69 55.43 64.40 79.68
Liabilities        
Accounts Payable 7.08 7.88 6.95 10.69
Debt in Current Liabilities 6.07 5.55 3.99 2.44
Total Current Liabilities 13.15 13.43 10.95 13.13
Long-Term Debt 11.01 12.47 13.92 15.37
Total Liabilities 27.50 29.28 28.48 31.65
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.00 0.00 0.00 0.00
Retained Earnings -251.03 -237.27 -224.16 -208.60
Treasury Stock NA NA NA NA
Total Stockholders' Equity 49.18 26.15 35.92 48.03
Total Liabilities and Stockholders' Equity 76.69 55.43 64.40 79.68

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -12.47 -10.38 -14.38 -11.13
Net Cash Provided by Investing Activities -0.38 -0.45 0.97 18.70
Net Cash Provided by Financing Activities 34.23 1.21 1.53 0.80

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.00-13.32--
12/20140.77-28.65-2.69
12/20151.75-39.75-1.71
12/20161.89-44.70-1.80
12/20171.92-63.39-2.20
Growth RatesInfinity----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/187521,53357.76




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.